Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Inks MammaPrint Distribution Deal for Middle East Region

NEW YORK (GenomeWeb) – Dutch molecular diagnostics firm Agendia announced today that it has signed an agreement to distribute its MammaPrint gene expression-based breast cancer test in the Middle East.

Lebanon-based Cryogene and its subsidiary, Mist, will distribute the CE-marked and FDA-cleared test for breast cancer recurrence. Financial and other terms of the deal were not disclosed.

"Our partnership with Cryogene and Mist is an important milestone in making our validated breast cancer recurrence assay available to the medical community in the Middle East," Marjolaine Baldo, Agendia's commercial VP for Europe, Middle East, and Africa, said in a statement.

Earlier this week, Agendia announced that the American Medical Association has granted MammaPrint a Category I MAAA Current Procedural Terminology code.